Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
ACAD's Cash to Debt is ranked higher than
98% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. ACAD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ACAD' s Cash to Debt Range Over the Past 10 Years
Min: 5.56  Med: 337.16 Max: 98090
Current: No Debt
5.56
98090
Equity to Asset 0.94
ACAD's Equity to Asset is ranked higher than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ACAD: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
ACAD' s Equity to Asset Range Over the Past 10 Years
Min: -2.13  Med: 0.78 Max: 0.98
Current: 0.94
-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
98% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ACAD' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
F-Score: 4
Z-Score: 48.06
M-Score: 52.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -4458.76
ACAD's Operating margin (%) is ranked lower than
89% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. ACAD: -4458.76 )
Ranked among companies with meaningful Operating margin (%) only.
ACAD' s Operating margin (%) Range Over the Past 10 Years
Min: -269855.74  Med: -967.44 Max: 35.82
Current: -4458.76
-269855.74
35.82
Net-margin (%) -4427.79
ACAD's Net-margin (%) is ranked lower than
89% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. ACAD: -4427.79 )
Ranked among companies with meaningful Net-margin (%) only.
ACAD' s Net-margin (%) Range Over the Past 10 Years
Min: -269578.69  Med: -923.87 Max: 35.93
Current: -4427.79
-269578.69
35.93
ROE (%) -64.13
ACAD's ROE (%) is ranked lower than
68% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. ACAD: -64.13 )
Ranked among companies with meaningful ROE (%) only.
ACAD' s ROE (%) Range Over the Past 10 Years
Min: -138.68  Med: -63.43 Max: 72.43
Current: -64.13
-138.68
72.43
ROA (%) -59.94
ACAD's ROA (%) is ranked lower than
73% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. ACAD: -59.94 )
Ranked among companies with meaningful ROA (%) only.
ACAD' s ROA (%) Range Over the Past 10 Years
Min: -78.95  Med: -54.79 Max: 34.38
Current: -59.94
-78.95
34.38
ROC (Joel Greenblatt) (%) -9272.16
ACAD's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. ACAD: -9272.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACAD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -21643.52  Med: -5397.08 Max: 2028.76
Current: -9272.16
-21643.52
2028.76
Revenue Growth (3Y)(%) -77.60
ACAD's Revenue Growth (3Y)(%) is ranked lower than
90% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ACAD: -77.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACAD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -77.6  Med: -47.5 Max: 71.7
Current: -77.6
-77.6
71.7
EBITDA Growth (3Y)(%) 62.90
ACAD's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. ACAD: 62.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACAD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.6  Med: -12.2 Max: 62.9
Current: 62.9
-42.6
62.9
EPS Growth (3Y)(%) 62.50
ACAD's EPS Growth (3Y)(%) is ranked higher than
94% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ACAD: 62.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACAD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.3  Med: -9.4 Max: 111.6
Current: 62.5
-55.3
111.6
» ACAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ACAD Guru Trades in Q4 2015

Louis Moore Bacon 100,000 sh (New)
Ron Baron 638,000 sh (unchged)
Paul Tudor Jones 14,405 sh (-6.02%)
Steven Cohen 303,800 sh (-84.90%)
» More
Q1 2016

ACAD Guru Trades in Q1 2016

Steven Cohen 2,222,700 sh (+631.63%)
Steven Cohen 450,000 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Ron Baron Sold Out
» More
Q2 2016

ACAD Guru Trades in Q2 2016

Steven Cohen 1,199,700 sh (-46.03%)
» More
Q3 2016

ACAD Guru Trades in Q3 2016

George Soros 17,645 sh (New)
Jana Partners 149,252 sh (New)
Steven Cohen 2,071,500 sh (+72.67%)
Steven Cohen 120,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CBPO, NAS:RARE, NYSE:XON, NAS:ICPT, OTCPK:BTGGF, NAS:TECH, NAS:GLPG, NAS:ALNY, NAS:KITE, NAS:JUNO, NAS:BLUE, NAS:LGND, NAS:PRTA, OTCPK:ABCZF, NAS:NKTR, NAS:SRPT, NAS:AGIO, NAS:SAGE, NAS:EXEL, NAS:DBVT » details
Traded in other countries:DR6.Germany,
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.

Ratios

vs
industry
vs
history
P/B 5.76
ACAD's P/B is ranked lower than
69% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. ACAD: 5.76 )
Ranked among companies with meaningful P/B only.
ACAD' s P/B Range Over the Past 10 Years
Min: 0.48  Med: 5.46 Max: 16.67
Current: 5.76
0.48
16.67
P/S 597.39
ACAD's P/S is ranked lower than
95% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. ACAD: 597.39 )
Ranked among companies with meaningful P/S only.
ACAD' s P/S Range Over the Past 10 Years
Min: 0.64  Med: 45.15 Max: 39600
Current: 597.39
0.64
39600
Current Ratio 15.42
ACAD's Current Ratio is ranked higher than
88% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ACAD: 15.42 )
Ranked among companies with meaningful Current Ratio only.
ACAD' s Current Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.05 Max: 46.41
Current: 15.42
2.27
46.41
Quick Ratio 15.31
ACAD's Quick Ratio is ranked higher than
89% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. ACAD: 15.31 )
Ranked among companies with meaningful Quick Ratio only.
ACAD' s Quick Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.05 Max: 46.41
Current: 15.31
2.27
46.41
Days Inventory 381.67
ACAD's Days Inventory is ranked lower than
89% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. ACAD: 381.67 )
Ranked among companies with meaningful Days Inventory only.
ACAD' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 381.67
Current: 381.67
0
381.67
Days Sales Outstanding 260.16
ACAD's Days Sales Outstanding is ranked lower than
94% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. ACAD: 260.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 239.08  Med: 2932.17 Max: 9801.15
Current: 260.16
239.08
9801.15
Days Payable 752.90
ACAD's Days Payable is ranked higher than
98% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. ACAD: 752.90 )
Ranked among companies with meaningful Days Payable only.
ACAD' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 752.9
Current: 752.9
0
752.9

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.60
ACAD's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. ACAD: -11.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -173.8  Med: -23.7 Max: -2
Current: -11.6
-173.8
-2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.90
ACAD's Price/Net Cash is ranked higher than
51% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. ACAD: 5.90 )
Ranked among companies with meaningful Price/Net Cash only.
ACAD' s Price/Net Cash Range Over the Past 10 Years
Min: 0.69  Med: 4.92 Max: 19.49
Current: 5.9
0.69
19.49
Price/Net Current Asset Value 5.75
ACAD's Price/Net Current Asset Value is ranked lower than
52% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. ACAD: 5.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACAD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.66  Med: 4.71 Max: 18.47
Current: 5.75
0.66
18.47
Price/Tangible Book 5.69
ACAD's Price/Tangible Book is ranked lower than
61% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. ACAD: 5.69 )
Ranked among companies with meaningful Price/Tangible Book only.
ACAD' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.63  Med: 4.29 Max: 18.19
Current: 5.69
0.63
18.19
Price/Median PS Value 12.88
ACAD's Price/Median PS Value is ranked lower than
97% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ACAD: 12.88 )
Ranked among companies with meaningful Price/Median PS Value only.
ACAD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 0.64 Max: 811.5
Current: 12.88
0.02
811.5
Earnings Yield (Greenblatt) (%) -8.76
ACAD's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. ACAD: -8.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACAD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -8.93  Med: 71.7 Max: 51153
Current: -8.76
-8.93
51153

More Statistics

Revenue (TTM) (Mil) $5.39
EPS (TTM) $ -2.14
Beta4.37
Short Percentage of Float29.16%
52-Week Range $16.64 - 42.49
Shares Outstanding (Mil)121.11

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 11 108 290 483
EPS ($) -2.19 -1.23 0.12 1.25
EPS w/o NRI ($) -2.19 -1.23 0.12 1.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ACAD

Headlines

Articles On GuruFocus.com
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Acadia Has Tough Road Ahead With Nuplazid Success Mar 14 2015 
Analysts Remain Bullish on Acadia Pharma Despite Drug Approval Delay Mar 13 2015 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
What's behind put volume in Acadia Dec 06 2016
ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACAD-US :... Dec 05 2016
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients... Dec 01 2016
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients... Dec 01 2016
Here is What Hedge Funds Think About ACADIA Pharmaceuticals Inc. (ACAD) Nov 28 2016
ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US :... Nov 23 2016
ACADIA PHARMACEUTICALS INC Financials Nov 16 2016
ACADIA Starts Phase II Schizophrenia Study on Pimavanserin Nov 16 2016
Blog Coverage Viking Presents New Clinical Data on VK2809 Nov 16 2016
Johnson & Johnson (JNJ), ACADIA Pharmaceuticals Inc. (ACAD): Healthcare Experts at March Altus Like... Nov 15 2016
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients... Nov 15 2016
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients... Nov 15 2016
Acadia Faces Education Battle With Parkinson's Drug: Goldman Nov 11 2016
Coverage initiated on ACADIA Pharmaceuticals by Goldman Nov 11 2016
ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACAD-US :... Nov 11 2016
ETF’s with exposure to ACADIA Pharmaceuticals, Inc. : November 10, 2016 Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)